Joachim Kreuzburg

Sartorius operates through two divisions: Bioprocess Solutions (the growth engine — single-use bioreactors, filtration systems, fluid management, cell culture media, and process analytics) and Lab Products & Services (laboratory instruments, balances, pipettes, and consumables). Sartorius' Bioprocess Solutions division is essential infrastructure for manufacturing biologic drugs — the fastest-growing category of pharmaceuticals that includes monoclonal antibodies, gene therapies, cell therapies, and vaccines. Single-use bioreactors and filtration systems have become the industry standard because they eliminate the need for cleaning validation between batches, reduce cross-contamination risk, and provide manufacturing flexibility. The company experienced a massive COVID-19 demand surge (driven by vaccine and therapy production) followed by a significant destocking period as pharmaceutical customers worked through excess inventory accumulated during the pandemic. The post-destocking recovery trajectory is a key focus for investors. Key stock drivers include biopharmaceutical industry bioprocessing spending, destocking cycle resolution, order intake trends, single-use technology adoption rates, cell and gene therapy manufacturing growth, competitive dynamics with Danaher/Cytiva, and the pace of biologics pipeline expansion.